Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, View ORCID ProfileLindsay N. Carpp, Avi Kenny, Marco Carone, View ORCID ProfileDavid Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team United States Government (USG) COVID-19 Immune Assays Team
doi: https://doi.org/10.1101/2023.10.15.23295628
Bo Zhang
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Youyi Fong
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
2Public Health Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Jonathan Fintzi
3Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
Eric Chu
4Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Holly E. Janes
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
2Public Health Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Lindsay N. Carpp
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Avi Kenny
5Department of Biostatistics, University of Washington; Seattle, WA, USA
Marco Carone
5Department of Biostatistics, University of Washington; Seattle, WA, USA
David Benkeser
6Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University; Atlanta, GA, USA
Lars W. P. van der Laan
7Department of Statistics, University of Washington; Seattle, Washington, USA
Weiping Deng
8Moderna, Inc.; Cambridge, MA, USA
Honghong Zhou
8Moderna, Inc.; Cambridge, MA, USA
Xiaowei Wang
8Moderna, Inc.; Cambridge, MA, USA
Yiwen Lu
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Chenchen Yu
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Bhavesh Borate
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Christopher R. Houchens
9Biomedical Advanced Research and Development Authority; Washington, DC, USA
Karen Martins
9Biomedical Advanced Research and Development Authority; Washington, DC, USA
Lakshmi Jayashankar
9Biomedical Advanced Research and Development Authority; Washington, DC, USA
Chuong Huynh
9Biomedical Advanced Research and Development Authority; Washington, DC, USA
Carl J. Fichtenbaum
10Division of Infectious Diseases, Department of Medicine, University of Cincinnati; Cincinnati, Ohio, USA
Spyros Kalams
11Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center; Nashville, TN, USA
Cynthia L. Gay
12Department of Medicine, Division of Infectious Diseases, UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine; Chapel Hill, NC, USA
Michele P. Andrasik
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
James G. Kublin
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
Lawrence Corey
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
13Department of Laboratory Medicine and Pathology, University of Washington; Seattle, WA, USA
Kathleen M. Neuzil
14Center for Vaccine Development and Global Health, University of Maryland School of Medicine; Baltimore, MD, USA
Frances Priddy
8Moderna, Inc.; Cambridge, MA, USA
Rituparna Das
8Moderna, Inc.; Cambridge, MA, USA
Bethany Girard
8Moderna, Inc.; Cambridge, MA, USA
Hana M. El Sahly
15Department of Molecular Virology and Microbiology, Baylor College of Medicine; Houston, TX, USA
Lindsey R. Baden
16Brigham and Women’s Hospital; Boston, MA, USA
Ruben O. Donis
9Biomedical Advanced Research and Development Authority; Washington, DC, USA
Richard A. Koup
17Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
Peter B. Gilbert
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
2Public Health Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
5Department of Biostatistics, University of Washington; Seattle, WA, USA
Dean Follmann
3Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
- COVE Post-Dose 3 Omicron COVID-19 Correlates Statistical Analysis Plan[supplements/295628_file02.pdf]
- Supplementary Materials[supplements/295628_file03.docx]
Posted October 15, 2023.
Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Lindsay N. Carpp, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team
medRxiv 2023.10.15.23295628; doi: https://doi.org/10.1101/2023.10.15.23295628
Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Lindsay N. Carpp, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team
medRxiv 2023.10.15.23295628; doi: https://doi.org/10.1101/2023.10.15.23295628
Subject Area
Subject Areas
- Addiction Medicine (398)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2911)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12693)
- Forensic Medicine (10)
- Gastroenterology (825)
- Genetic and Genomic Medicine (4554)
- Geriatric Medicine (413)
- Health Economics (724)
- Health Informatics (2903)
- Health Policy (1067)
- Hematology (384)
- HIV/AIDS (920)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4321)
- Nursing (233)
- Nutrition (634)
- Oncology (2255)
- Ophthalmology (642)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (277)
- Palliative Medicine (83)
- Pathology (496)
- Pediatrics (1194)
- Primary Care Research (493)
- Public and Global Health (6903)
- Radiology and Imaging (1521)
- Respiratory Medicine (913)
- Rheumatology (435)
- Sports Medicine (381)
- Surgery (483)
- Toxicology (60)
- Transplantation (209)
- Urology (178)